Sangamo BioSciences | SGMO - Selling And Administration Expenses


Sangamo BioSciences reported $9.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.58B 354M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.42B 381M Jun/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 2.92B 1.16B Mar/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026